European Psychiatry
June 1, 2026
N. Aguayo-Verdugo, N. Ulloa-Chamblás, R. Zúñiga-Tapia et al.
Introduction University students, particularly in health-related fields, face rising levels of stress, anxiety, and depression, which negatively affect academic performance, social engagement, and overall well-being. Post-pandemic challenges, such as social isolation, uncertainty, and abrupt transitions to online learning, have exacerbated these issues. Mindfulness-based interventions (MBIs)...
European Psychiatry
June 1, 2026
P.-M. Llorca, Ludovic Samalin, Emilie Olié et al.
Introduction: Esketamine nasal spray (ESK) was approved in 2019 in Europe for adults with Treatment-Resistant Depression (TRD), defined as inadequate response to at least two different antidepressants during the current moderate to severe depressive episode Objectives: To assess patient-reported outcomes related to symptomatology, quality of life, and occupational impairment over 12 months...
European Psychiatry
June 1, 2026
Nawfel Ayad, Samer Makhoul
Introduction Treatment-resistant depression (TRD) poses a significant clinical challenge, with limited evidence guiding long-term pharmacological strategies. Esketamine, a glutamatergic modulator, has demonstrated short-term efficacy in TRD, but data on its extended use in real-world settings remains scarce Objectives This study aimed to evaluate the long-term effectiveness and tolerability of...
European Psychiatry
June 1, 2026
A. Kuzma-Hunt, Z. Hamadeh, V. Tsang
Introduction Ketamine-assisted therapy shows rapid benefit in treatment-resistant depression, anxiety, and PTSD (Walsh et al. BJPsych Open 2022;8:e19). The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a unique 12-week program that combines 12 Community of Practice (group therapy) sessions and three ketamine medicine sessions (Tsang et al. Ther Adv Psychopharmacol...
European Psychiatry
June 1, 2026
A. K. Sikora
Abstract Catatonia is a potentially life-threatening psychomotor syndrome that can complicate substance intoxication and may be missed in acute psychiatric and addiction settings. Synthetic cannabinoids (e.g., Spice/K2) are associated with severe neuropsychiatric presentations including agitation, psychosis, autonomic instability, and diagnostic ambiguity. This talk presents a clinical case of...
European Psychiatry
June 1, 2026
T. Sagues, A. Barnes, C. Fernández et al.
Introduction Intranasal esketamine has emerged as an innovative option for the management of treatment-resistant depression (TRD), offering a novel mechanism of action and rapid antidepressant effects. However, evidence regarding the clinical trajectory after treatment discontinuation remains limited, raising questions about the durability of its therapeutic benefits and the optimal maintenance...
European Psychiatry
June 1, 2026
Cristina Serritella, L. Iorio, F. Ferraiuolo et al.
Introduction Intranasal esketamine provides a rapid therapeutic option for treatment-resistant depression but can induce transient blood pressure increases. The influence of psychopathological traits on these cardiovascular responses remains largely unexplored. Objectives The present study aims to investigate the acute effects of intranasal esketamine on systolic and diastolic blood pressure as...
European Psychiatry
June 1, 2026
M. A. K. Guirguis, H. Raai
Introduction Auditory hallucinations are a debilitating manifestation of trauma in children. Voice-hearing is common among youth exposed to multiple traumatic experiences and is associated with cognitive mechanisms that contribute to the persistence of symptoms [1]. These experiences can cause severe distress, disrupt development, and may increase risk of self-harm mediated by hallucinatory...
European Psychiatry
June 1, 2026
M. P. Rapagnani, L. Veronesi, F. Sartini
Introduction In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments of antidepressants. Esketamine (the S-enantiomer of ketamine) nasal spray, administered in combination with either a selective serotonin reuptake inhibitor (SSRI) or a serotonine-norepinephrine reuptake inhibitor (SNRI), is the only treatment approved in Europe...
European Psychiatry
June 1, 2026
J. Tripp, G. Smagin
Introduction MM120 (lysergide D-tartrate, LSD, CAS 32426-57-6) is under development as a potential treatment for generalized anxiety disorder and major depressive disorder. MM120 may elicit profound lasting psychological changes through interaction with brain 5-HT1A, 1B, 2A, 2C, 6 and 7 receptors, among others, while the complete mechanism is not clear. Objectives The study was performed to...
European Psychiatry
June 1, 2026
L. Jishkariani, D. Zurabashvili, K. Gigolashvili et al.
Introduction Cannabis decriminalization raises concerns about its psychiatric impact, particularly on psychosis risk. As cannabis became decriminalized in Georgia in 2018, questions emerged regarding changes in substance-related and acute psychotic disorders. Examining these trends is essential to guide prevention, treatment, and policy in a shifting drug landscape. Objectives This study aims...
European Psychiatry
June 1, 2026
M. A. Andreo-Vidal, M. Calvo-Valcarcel, Claudia Rodríguez-valbuena et al.
Introduction The differential diagnosis between conversion disorders and psychotic episodes can present a significant clinical challenge. Both conditions may share striking symptoms such as mutism, immobility, altered states of consciousness, and bizarre behavior, which can lead to diagnostic confusion—especially in emergency settings. Objectives This case study aims to analyze the atypical...
European Psychiatry
June 1, 2026
Jesús García-Jiménez, S. Posik, B. Herrejón et al.
Introduction Treatment-resistant depression (TRD) is highly burdensome. Intranasal esketamine is effective, yet hospital-centric delivery adds travel and continuity barriers that may hinder adherence and outcomes. We hypothesize that community outpatient, patient-proximal delivery —often with the patient’s usual psychiatrist—improves effectiveness, engagement and acceptability, consistent with...
European Psychiatry
June 1, 2026
Lewis Mehl‐Madrona, Barbara Mainguy
Introduction Creative arts therapies, particularly drama therapy techniques, are useful in psychotherapy Objectives We aim to show how the creative arts can be used in the treatment of psychosis and in training people about the experience of psychosis. Methods The techniques can be used in one-on-one appointments or in groups. Useful approaches include the client’s making figures to represent...
European Psychiatry
June 1, 2026
Agnieszka Mechlińska, Damian Swieczkowski, Aleksander Kwaśny et al.
Introduction MDMA (3,4-methylenedioxymethamphetamine)–assisted therapy has gained growing scientific attention as a potential treatment for post-traumatic stress disorder and other mental health conditions. Although clinical studies suggest potential benefits, concerns remain regarding cardiovascular safety, methodological rigor, and variability in psychotherapeutic support (Singh et al . CNS...
European Psychiatry
June 1, 2026
I. C. Mândraș, A. L. Comșa
Introduction Suicidality represents a major clinical and public health challenge, particularly among patients with treatment-resistant depression (TRD), who carry a disproportionately high risk of suicide. Traditional antidepressants often have delayed onset and limited efficacy in reducing suicidal ideation in this high-risk population, highlighting the need for rapid-acting interventions....
European Psychiatry
June 1, 2026
M. Pastre, F. Pereira, T. Gibert et al.
Introduction Treatment-resistant depression (TRD) remains a major clinical challenge, with limited efficacy of available therapies. Psilocybin, a serotonergic psychedelic, has shown promising antidepressant effects. As recent studies have shown altered default mode network activity following psilocybin administration, further neuroimaging research in clinical populations is needed to clarify...
European Psychiatry
June 1, 2026
V. Sharma, S. Ather, A. Sič et al.
Introduction Suicide is a leading cause of death in the psychiatric population. The existing modes of treatment (pharmacological and psychotherapeutic) for suicidality are effective but have longer onset, this delay causing a dangerous therapeutic gap in an acute crisis. We compare the two fast-acting treatments, the newer psychopharmacological agent Ketamine and well-established...
European Psychiatry
June 1, 2026
O. Płaza, Robert Madejek, M. M. Dutsch-Wicherek et al.
Introduction Treatment-resistant depression (TRD), which affects about 30% of patients with major depressive disorder, emerges when patients do not respond adequately to at least two antidepressant trials of proper dose and duration. The EMA approved esketamine nasal spray, the first registered psychedelic medication, in 2019 for TRD treatment. In July 2023, Poland launched B.147, the country’s...
European Psychiatry
June 1, 2026
W. Aldulaimy, A. Shah
Introduction TBI patients often suffer from severe, treatment-resistant depression and PTSD. Ketamine shows promise in non-TBI populations, but its efficacy in TBI patients needs exploration for efficacy and tolerability. Objectives Evaluate ketamine’s clinical effectiveness and safety (PHQ-9, GAD-7, PCL-5 scores) in post-TBI patients, comparing IM, intranasal, and oral routes. Methods Design:...
European Psychiatry
June 1, 2026
Z. Onat, Ş. Kükürt
Introduction Multiple sclerosis (MS) is a chronic neuroinflammatory disorder frequently associated with psychiatric comorbidities such as depression, anxiety, bipolar disorder, and psychosis. However, dissociative disorders in MS are rarely reported and remain underexplored. Dissociative amnesia accompanied by regressive behaviors is likely influenced by both the psychological burden of MS and...
European Psychiatry
June 1, 2026
Alexandros Argyriadis, E. Kleanthous, E. Patelarou et al.
Introduction Digital addiction, particularly in the context of excessive smartphone and social media use, has been associated with impaired cognitive control, emotional dysregulation, and social withdrawal. Cognitive Behavioral Therapy (CBT) is widely recognized for addressing maladaptive thought patterns, while mindfulness-based strategies enhance present-moment awareness and reduce...
European Psychiatry
June 1, 2026
A. Arshad, A. Khalid, M. Bilal et al.
Introduction Dissociative fugue is a rare condition, falling within the spectrum of dissociative identity disorders as per the DSM-V criteria. This condition is marked by an abrupt and unforeseen departure from one’s usual routine, accompanied by memory lapses. Its occurrence within the general population is estimated at a mere 0.2%, and individuals may linger in this fugue state for a few days...
European Psychiatry
June 1, 2026
Sofia von Humboldt, Isabel Leal
Introduction Meditation may serve as a protective factor for mental well-being in older adults, helping them cope with the ongoing challenges of chronic illness. Objectives The objectives are to: 1) explore the emotional experiences of meditation among older adults living with chronic diseases, and 2) examine the impact of meditation on their mental health. Methods The study involved 426...
European Psychiatry
June 1, 2026
H. Morrin, L. Nicholls, M. Levin et al.
Introduction Large language models (LLMs) are becoming ubiquitous, offering scalable, responsive and seemingly empathic dialogue. While their therapeutic potential has attracted attention, emerging reports highlight risks of “AI-associated delusions,” where interactions with conversational agents appear to amplify psychotic thinking. These interactions may validate persecutory or grandiose...